JOP20190178A1 - تركيبة صيدلانية تتضمن مشتق أوكسازين واستخدامها في علاج أو الوقاية من مرض الزهايمر - Google Patents

تركيبة صيدلانية تتضمن مشتق أوكسازين واستخدامها في علاج أو الوقاية من مرض الزهايمر

Info

Publication number
JOP20190178A1
JOP20190178A1 JOP/2019/0178A JOP20190178A JOP20190178A1 JO P20190178 A1 JOP20190178 A1 JO P20190178A1 JO P20190178 A JOP20190178 A JO P20190178A JO P20190178 A1 JOP20190178 A1 JO P20190178A1
Authority
JO
Jordan
Prior art keywords
alzheimer
disease
prevention
treatment
pharmaceutical composition
Prior art date
Application number
JOP/2019/0178A
Other languages
English (en)
Inventor
Dragutin Knezic
Rita Ramos
Vishal Shamji Koradia
Miloud Achour
Edgar John
Michael Juhnke
Bruno Galli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20190178A1 publication Critical patent/JOP20190178A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة صيدلانية تتضمن مشتق أوكسازين مثبط BACE-1، وعملية لتحضيرها، واستخدامها في العلاج أو الوقاية من مرض الزهايمر
JOP/2019/0178A 2017-01-20 2017-06-16 تركيبة صيدلانية تتضمن مشتق أوكسازين واستخدامها في علاج أو الوقاية من مرض الزهايمر JOP20190178A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17152481 2017-01-20

Publications (1)

Publication Number Publication Date
JOP20190178A1 true JOP20190178A1 (ar) 2019-07-16

Family

ID=57890668

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2019/0178A JOP20190178A1 (ar) 2017-01-20 2017-06-16 تركيبة صيدلانية تتضمن مشتق أوكسازين واستخدامها في علاج أو الوقاية من مرض الزهايمر
JOP/2019/0180A JOP20190180A1 (ar) 2017-01-20 2017-06-16 مشتق أوكسازين حر القاعدة في صورة بلورية

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2019/0180A JOP20190180A1 (ar) 2017-01-20 2017-06-16 مشتق أوكسازين حر القاعدة في صورة بلورية

Country Status (21)

Country Link
US (2) US20190388428A1 (ar)
EP (2) EP3570820A1 (ar)
JP (2) JP2020505367A (ar)
KR (1) KR20190126291A (ar)
CN (1) CN110167535A (ar)
AR (1) AR110758A1 (ar)
AU (3) AU2018208870A1 (ar)
BR (2) BR112019014234A2 (ar)
CA (2) CA3048346A1 (ar)
CL (1) CL2019002020A1 (ar)
CO (2) CO2019007671A2 (ar)
CR (1) CR20190333A (ar)
IL (2) IL267640A (ar)
JO (2) JOP20190178A1 (ar)
MX (2) MX2019008603A (ar)
PE (2) PE20191250A1 (ar)
RU (1) RU2019126022A (ar)
SG (2) SG11201905116PA (ar)
TW (1) TW201828943A (ar)
UY (1) UY37572A (ar)
WO (2) WO2018134761A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019142111A1 (en) * 2018-01-18 2019-07-25 Novartis Ag Salt forms of an oxazine derivative bace inhibitor
CN112661667B (zh) * 2020-12-28 2023-02-03 浦拉司科技（上海）有限责任公司 一种三氟乙脒的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2824220C (en) * 2011-01-13 2020-09-01 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders

Also Published As

Publication number Publication date
JOP20190180A1 (ar) 2019-07-20
TW201828943A (zh) 2018-08-16
CO2019007670A2 (es) 2019-07-31
MX2019008601A (es) 2019-09-10
UY37572A (es) 2018-08-31
WO2018134760A1 (en) 2018-07-26
EP3571195A1 (en) 2019-11-27
KR20190126291A (ko) 2019-11-11
PE20191250A1 (es) 2019-09-18
WO2018134761A1 (en) 2018-07-26
BR112019014234A2 (pt) 2020-03-17
AR110758A1 (es) 2019-05-02
AU2018209442A1 (en) 2019-06-20
AU2020289738A1 (en) 2021-01-21
US20190388428A1 (en) 2019-12-26
IL268131A (en) 2019-09-26
BR112019014825A2 (pt) 2020-02-27
PE20191346A1 (es) 2019-09-30
RU2019126022A3 (ar) 2021-10-19
CO2019007671A2 (es) 2019-07-31
CA3046304A1 (en) 2018-07-26
CA3048346A1 (en) 2018-07-26
IL267640A (en) 2019-08-29
SG11201905528XA (en) 2019-08-27
JP2020505367A (ja) 2020-02-20
JP2020505363A (ja) 2020-02-20
EP3570820A1 (en) 2019-11-27
SG11201905116PA (en) 2019-08-27
MX2019008603A (es) 2019-09-10
AU2018208870A1 (en) 2019-07-04
CN110167535A (zh) 2019-08-23
CL2019002020A1 (es) 2019-10-04
US20200048237A1 (en) 2020-02-13
RU2019126022A (ru) 2021-02-20
CR20190333A (es) 2019-09-13

Similar Documents

Publication Publication Date Title
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MY199220A (en) Heterocyclic compounds as immunomodulators
PH12019502782A1 (en) Fixed dose formulations
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
WO2016109217A3 (en) Btk inhibitors
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
MX2016008968A (es) Compuestos organicos.
MX2019008603A (es) Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.
MY185942A (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
PH12018502703A1 (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
PH12017501694B1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MX2017012188A (es) Inhibidores de beta-secretasa 1 (bace1).
WO2019209232A3 (en) The use of terpenic coumarine derivative molecules in the treatment of cancer disease
EP4537846A3 (en) Anavex2-73 for the treatment of alzheimer s disease
JOP20190081A1 (ar) مشتق أوكسازين للاستخدام في علاج أو الوقاية من اعتلال وعائي دماغي نشواني